CSIMarket Company Name, Ticker, Industry, else..
 
Cancer Capital Corp   (CNCL)
Other Ticker:  
 
    Sector • Financial    Industry • Blank Checks
   Industry • Blank Checks
   Sector • Financial
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 6
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 0
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Cancer Capital Corp
Cancer Capital Corp is a financial services company that specializes in providing investment capital for cancer research and development. Their focus is on supporting and financing small and medium-sized biotech companies that are dedicated to finding new breakthroughs and treatments for cancer. The company aims to bridge the funding gap in cancer research and help bring promising therapies to market. Cancer Capital Corp also works closely with academic institutions, pharmaceutical companies, and other stakeholders in the oncology field to foster collaboration and accelerate the development of innovative cancer treatments.


   Company Address: 440 E. 400 South Salt Lake City 84111 UT
   Company Phone Number: 323-2395   Stock Exchange / Ticker: CNCL


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Cancer Capital Corp

Blank Checks Company CNCL Sees Decline in Corporate Behavior in Q1 2024

As Wall Street analysts and investors eagerly awaited the latest financial results from CNCL for the first quarter of 2024, many were taken by surprise with the unexpected moderations in the company's business operations. The operating deficit of $-0.01005 million during this period was not anticipated, leading to some concerns among stakeholders.
While the company has not yet disclosed its revenue figures for this quarter, it is clear that there has been a significant decline in financial performance compared to the same time last year. In the first quarter of 2023, CNCL reported an operating deficit of $-0.005699 million, indicating that the business has been struggling to maintain its profitability.
Cancer Capital Corp

Cancer Capital Corp , deterioration in the corporate performance during the first quarter of 2023

Investors have been closely monitoring Cancer Capital Corp's (CNCL) financial performance during the earnings cycle of fiscal January to March 31, 2023. While they did not anticipate any significant changes at the company's top-line, they noted the operating deficit of $-0.005699 million in the same quarter. This figure has seen a decrease since the first quarter of 2021, from $-0.00282 million, but investors are still very interested in when the company will start to generate revenue.
It's not uncommon for corporations to go through rough patches as they strive to identify successful sources of revenue. The first quarter of 2023 was one such rough period for Cancer Capital Corp. During this time, the company saw a net loss of $-0.011 million. However, this could be a temporary hurdle that the company will overcome through adjustments and strategic planning.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com